Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients

Objectives: This study aimed to explore factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer (aNSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods: A total of 101 patients with aNSCLC receiving ICIs were included. The association bet...

Full description

Bibliographic Details
Main Authors:	Yahua Wu, Haishan Wu, Mingqiang Lin, Tianxiu Liu, Jiancheng Li
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	Translational Oncology
Subjects:	Non-small cell lung cancer Immune checkpoint inhibitors Pre-treatment prognostic score Immunotherapy respond Immune-related adverse events
Online Access:	http://www.sciencedirect.com/science/article/pii/S193652332100259X

Similar Items

Short review of immunotherapy toxicity
by: Ivana Canjko, et al.
Published: (2021-01-01)

Rheumatological Adverse Events Following Immunotherapy for Cancer
by: Ioana Cretu, et al.
Published: (2022-01-01)

Efficacy of immunotherapy in small cell lung cancer: A retrospective stude
by: Marina A. Lyadova, et al.
Published: (2024-08-01)

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
by: Laura Kalfeist, et al.
Published: (2022-02-01)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
by: Yuqing He, et al.
Published: (2021-09-01)

Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center
by: João Queirós Coelho, et al.
Published: (2024-02-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
by: Huixia Li, et al.
Published: (2023-04-01)

Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer
by: Zachary J. Brown, et al.
Published: (2017-11-01)

Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis
by: Jiawei Xu, et al.
Published: (2022-01-01)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
by: Yuxuan Hao, et al.
Published: (2022-08-01)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
by: Xiaoyan Si, et al.
Published: (2020-03-01)

Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis
by: Xiao-Tong Zhang, et al.
Published: (2022-11-01)

Toxicities of Immunotherapy for Small Cell Lung Cancer
by: Yang Fu, et al.
Published: (2021-05-01)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
by: Tadashi Nishimura, et al.
Published: (2024-04-01)

Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy
by: Anna Rudzińska, et al.
Published: (2024-11-01)

Immunotherapy in elderly patients
by: M. A. Lyadova, et al.
Published: (2021-08-01)

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
by: Courtney H. Coschi, et al.
Published: (2021-11-01)

A case of polyserositis, chylous ascites and hepatitis induced by immune checkpoint-inhibitors
by: Marta Castelli, et al.
Published: (2024-05-01)

A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors
by: Oren Levine, et al.
Published: (2017-08-01)

Overview and management of toxicities of immune checkpoint-blocking drugs
by: Economopoulou Panagiota, et al.
Published: (2016-03-01)

A clinical case of treatment of a patient with acute adrenal insufficiency after combined immunotherapy (nivolumab + ipilimumab). Prospects for a return to immunotherapy after severe complications of immunotherapy
by: К. К. Laktionov, et al.
Published: (2021-06-01)

Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer
by: Jun NI, et al.
Published: (2021-03-01)

Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer
by: Kecheng Lou, et al.
Published: (2022-05-01)

Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis
by: Yuqian Feng, et al.
Published: (2024-01-01)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
by: I. Puzanov, et al.
Published: (2017-11-01)

Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice
by: Liliana Gabriela Popa, et al.
Published: (2024-02-01)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
by: Akhil Kapoor, et al.
Published: (2022-10-01)

Immunotherapy for Advanced Non-small Cell Lung Cancer: Research Progress and Perspectives
by: Jingyi WANG, et al.
Published: (2024-06-01)

Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study
by: Satoshi Endo, et al.
Published: (2023-01-01)

A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review
by: Yoon-E Shin, et al.
Published: (2024-10-01)

Hepatotoxicity induced by immune checkpoint inhibitors
by: Flaviu Muresan, et al.
Published: (2024-10-01)

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors
by: Emma Titmuss, et al.
Published: (2024-03-01)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseResearch in context
by: Chaozheng Zhou, et al.
Published: (2023-05-01)

Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
by: Prasanna Duraisamy, et al.
Published: (2023-07-01)

Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events
by: Ryan Holstead, et al.
Published: (2020-12-01)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
by: Taiseer Al-Rajabi, et al.
Published: (2023-09-01)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01)

Clinical characteristics and biomarkers of severe immune checkpoint inhibitor-related pneumonitis triggered by immunotherapy followed by radiation: a case report
by: Yan Zhu, et al.
Published: (2024-11-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)